Withdrawn from the market (safety)
Encainide
ENKAID
What it isClass IC antiarrhythmic; withdrawn.
Why this oneIt suppressed ventricular ectopy effectively, which is exactly why it was trialled.
What limits it⚑ CAST showed it INCREASED mortality after myocardial infarction — the trial that ended surrogate-endpoint prescribing in cardiology.
FDA-approved for
- ventricular arrhythmias (withdrawn 1991) (1986)
⚠ BOXED WARNING
- Proarrhythmia and excess mortality after myocardial infarction
Classes and tags
Clinical profile
Mechanism of action: Encainide ballicule
